Patent application number | Description | Published |
20100048571 | Organic Compounds - The present disclosure relates to XIAP inhibitor compound of the formula I: | 02-25-2010 |
20100076013 | Methods of Treatment - The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the use of compounds that inhibit the binding of the Smac protein to IAPs (“IAP inhibitor”). The present invention also relates to the use of IAP inhibitors for the preparation of a medicament to treat hematological malignancies, including AML. | 03-25-2010 |
20100249405 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 09-30-2010 |
20100316573 | Organic Compounds - A method to predict which patients will respond to a IAP inhibiting compound comprising:
| 12-16-2010 |
20110015232 | Pyrrolydine Derivatives as IAP Inhibitors - The present invention relates to novel IAP inhibitor compounds of: Formula (I). | 01-20-2011 |
20110065726 | Organic Compounds - The present invention is directed to a compound of the formula: | 03-17-2011 |
20110281875 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 11-17-2011 |
20120196793 | BIOMARKERS FOR IAP INHIBITOR COMPOUNDS - A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels. | 08-02-2012 |
20130005663 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS - The present invention is directed to a compound of the formula: | 01-03-2013 |
20140004101 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | 01-02-2014 |
Patent application number | Description | Published |
20080242658 | Inhibitors of Iap - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula I | 10-02-2008 |
20090005411 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 01-01-2009 |
20090069294 | Organic Compounds - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 03-12-2009 |
20100056467 | COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS - The present invention relates to methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the Smac protein to IAPs (“IAP inhibitor”) and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; and a commercial package comprising said combination. The present invention also relates to the use of IAP inhibitors in combination with one or more pharmaceutically active agents for the preparation of a medicament to treat hematological malignancies, including AML. | 03-04-2010 |
20100324083 | Combinations of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 12-23-2010 |
20110251134 | COMBINATION OF (A) A DNA TOPOSOMERASE INHIBITOR AND (B) AN IAP INHIBITOR - The invention relates to a pharmaceutical combination which comprises (a) a DNA topoisomerase inhibitor compound and (b) a compound that inhibits the caspase-9 inhibiting properties of an inhibitor of apoptosis protein (IAP) for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human. | 10-13-2011 |
20110281845 | ORGANIC COMPOUNDS - The present disclosure relates to XIAP inhibitor compounds of the formula I. | 11-17-2011 |
20110319614 | Organic Compounds - The present invention relates to novel IAP inhibitor compounds of formula I: | 12-29-2011 |
20120129895 | METHODS OF TREATMENT - The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. | 05-24-2012 |
20120207769 | Inhibitors of IAP - Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I). | 08-16-2012 |
20130085153 | COMBINATION OF AN IAP INHIBITOR AND A TAXANE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE - The invention provides a pharmaceutical combination comprising:
| 04-04-2013 |
20130217719 | Combination of Organic Compounds - The invention provides a pharmaceutical combination comprising:
| 08-22-2013 |
20140024687 | Combinations of Vascular Disrupting Agents with Inhibitor of Apoptosis Proteins Antagonists - The invention relates to combinations comprising a vascular disrupting agent (VDA) with IAP antagonists, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. | 01-23-2014 |